{
    "nctId": "NCT00123929",
    "briefTitle": "Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer",
    "officialTitle": "Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "correlation of genetic tumoral pattern with response to docetaxel versus doxorubicin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced, inoperable breast carcinoma or stage II not amenable to breast preserving surgery (amendment introduced on november 2006)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\>75\n* Cardiac disease; LEFT \\<50%\n* Hyperbilirubinemia",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}